W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Miasta: Gdańsk, Gliwice, Kraków, Poznań i 2 inne miastaWiek: od 0 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Miasta: Białystok, Poznań, WarszawaWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Miasta: Poznań, Warszawa, WrocławWiek: do 17.99 latSponsor: Sanofi-Aventis Recherche & Developpement
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza II/III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Miasta: Bydgoszcz, Kraków, Lublin, Poznań i 2 inne miastaWiek: do 64 latSponsor: Ospedale Pediatrico Bambino Gesu
RekrutujeFaza II
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Miasta: Opole, Poznań, WarszawaWiek: do 64 latSponsor: Sab Biotherapeutics Inc.
RekrutujeFaza III
SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled…
Miasta: Białystok, Gdańsk, Kraków, Lublin i 4 inne miastaWiek: do 17.99 latSponsor: Medical University Of Warsaw
RekrutujeFaza II/III
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic…
Miasta: Białystok, Bydgoszcz, Lublin, Olsztyn i 4 inne miastaWiek: do 17.99 latSponsor: Helsinn Healthcare S.A.
RekrutujeFaza II/III
Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 17.99 latSponsor: Medical University Of Lodz
RekrutujeFaza III
Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome
Miasta: Białystok, Gdańsk, Kraków, Lublin i 5 innych miastWiek: do 17.99 latSponsor: Medical University Of Gdansk
RekrutujeFaza III
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 9 innych miastWiek: do 64 latSponsor: Medical University Of Gdansk
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 64 latSponsor: Universita Degli Studi Di Milano Bicocca
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Miasta: Białystok, Bydgoszcz, Chorzów, Gdańsk i 12 innych miastWiek: do 17.99 latSponsor: Princess Maxima Center For Pediatric Oncology
RekrutujeFaza III
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Miasta: Białystok, Bydgoszcz, Katowice, Lublin i 4 inne miastaWiek: od 0 latSponsor: Actelion Pharmaceuticals Ltd.
RekrutujeFaza III
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Miasta: Białystok, Bydgoszcz, Chorzów, Gdańsk i 12 innych miastWiek: do 17.99 latSponsor: Universitaetsklinikum Muenster AöR
RekrutujeFaza III
Paediatric Hepatic International Tumour Trial
Miasta: Białystok, Gdańsk, Katowice, Kraków i 5 innych miastWiek: do 64 latSponsor: The University Of Birmingham
Rekrutacja wkrótceFaza II
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Miasta: Gdańsk, Kraków, Poznań, WrocławWiek: do 64 latSponsor: Pediatric Research International GmbH